Vestor Capital LLC Lowers Stock Position in Stryker Co. (NYSE:SYK)

Vestor Capital LLC lessened its holdings in Stryker Co. (NYSE:SYK) by 21.4% during the second quarter, Holdings Channel.com reports. The firm owned 275 shares of the medical technology company’s stock after selling 75 shares during the quarter. Vestor Capital LLC’s holdings in Stryker were worth $67,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Freedom Wealth Alliance LLC purchased a new stake in Stryker in the 4th quarter valued at approximately $26,000. Quarry LP acquired a new stake in shares of Stryker during the 1st quarter valued at approximately $27,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Stryker during the 2nd quarter valued at approximately $31,000. Altshuler Shaham Ltd acquired a new stake in shares of Stryker during the 1st quarter valued at approximately $33,000. Finally, Cascade Investment Advisors Inc. acquired a new stake in shares of Stryker during the 1st quarter valued at approximately $34,000. Hedge funds and other institutional investors own 76.24% of the company’s stock.

Stryker Stock Up 0.2 %

Shares of Stryker stock opened at $283.64 on Thursday. The company has a fifty day moving average price of $275.05 and a 200 day moving average price of $282.57. The company has a current ratio of 1.48, a quick ratio of 0.83 and a debt-to-equity ratio of 0.58. Stryker Co. has a twelve month low of $216.55 and a twelve month high of $306.93. The stock has a market cap of $107.75 billion, a price-to-earnings ratio of 42.08, a price-to-earnings-growth ratio of 2.69 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.03. Stryker had a net margin of 13.00% and a return on equity of 22.62%. The firm had revenue of $4.90 billion during the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the prior year, the company earned $2.12 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Equities research analysts forecast that Stryker Co. will post 10.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $325.00 price target on shares of Stryker in a research report on Thursday, August 17th. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Monday, November 6th. Roth Mkm restated a “buy” rating and set a $345.00 price objective on shares of Stryker in a research report on Thursday, November 9th. Morgan Stanley lifted their price objective on Stryker from $295.00 to $300.00 and gave the stock an “equal weight” rating in a research report on Monday, August 7th. Finally, Barclays lifted their price objective on Stryker from $321.00 to $335.00 and gave the stock an “overweight” rating in a research report on Monday, August 7th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $311.30.

Insider Buying and Selling

In other Stryker news, insider Viju Menon sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $289.00, for a total value of $1,445,000.00. Following the completion of the transaction, the insider now directly owns 6,994 shares of the company’s stock, valued at approximately $2,021,266. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.90% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.